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Background: RNA viruses rapidly accumulate genetic variation, which can give rise to synthetic lethal (SL) and
deleterious (SD) mutations. Synthetic lethal mutations (non-lethal when alone but lethal when combined in one
genome) have been studied to develop cancer therapies. This principle can also be used against fast-evolving
RNA-viruses. Indeed, targeting protein sites involved in SD + SL interactions with a drug would render any mutation
of such sites, lethal.
Results: Here, we set up a strategy to detect intragenic pairs of SL and SD at the surface of the protein to predict
less escapable drug target sites. For this, we detected SD + SL, studying HIV protease (PR) and reverse transcriptase
(RT) sequence alignments from two groups of VIH+ individuals: treated with drugs (T) or not (NT). Using a series of
statistical approaches, we were able to propose bona fide SD + SL couples. When focusing on spatially close
co-variant SD + SL couples at the surface of the protein, we found 5 SD + SL groups (2 in the protease and 3 in the
reverse transcriptase), which could be good candidates to form pockets to accommodate potential drugs.
Conclusions: Thus, designing drugs targeting these specific SD + SL groups would not allow the virus to mutate
any residue involved in such groups without losing an essential function. Moreover, we also show that the
selection pressure induced by the treatment leads to the appearance of new mutations, which change the mutational
landscape of the protein. This drives the existence of differential SD + SL couples between the drug-treated and
non-treated groups. Thus, new anti-viral drugs should be designed differently to target such groups.
Reviewers: This article was reviewed by Neil Greenspan Csaba Pal and István Simon.
Keywords: Synthetic lethals, Drug targets, Drug design, RNA virusesBackground
Classical SL genetic interactions involve non-lethal muta-
tions (carried by two or more genes) whose combination
leads to cell death. They have been extensively used to
study gene-product interactions in the secretion pathway
of yeast [1] and bacteria [2]. Then, they were used to de-
velop anti-cancer therapies [3-6] by pinpointing a gene
(say, X) whose inactivation forms a pair of SL with a mu-
tated cancer-causing gene. In this context, the drug will
target gene X and not the gene responsible for the disease.
The synthetic lethality relationship appears when the
product of gene X is rendered non-functional by the
action of the drug. Thus, the existence of both non-
functional proteins provokes a lethal phenotype and leads* Correspondence: anne.vanet@univ-paris-diderot.fr
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unless otherwise stated.to cancer cell death. The effect of the drug on normal
cells, would not change their phenotype, and thus should
not induce any secondary effects. Based on this paradigm,
we describe a slightly different concept to uncover new
druggable targets in RNA viruses using an intragenic SL-
based strategy [7]. Indeed, RNA-viruses can escape drugs
[8] and vaccines [9], due to mutation of the targets against
which such therapeutic molecules are developed. To cir-
cumvent this problem, pocket-binding drugs targeting
viral fundamental functions should be pinpointed, so that
the virus cannot mutate without losing the relevant essen-
tial function (Figure four in [6]). Invariant residues fulfill
this condition but they are rare in the proteins of RNA-
viruses. It is this notion, of “invariance”, that we extend to
a group of residues. Intragenic SL and synthetic deleteri-
ous (SD) can be exploited for this purpose. For simplicity,
we call SDL the ensemble of SD + SL. A group of aminoal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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dues) and located at the protein surface, can provide a
suitable therapeutic target. These residues should be either
invariant or being members of the same SL group. Due to
these two features, essentiality for protein function and
invariance, these targets are unique in that they might
minimize or even prevent viral escape to treatment.
Various studies have been performed to describe pair-
wise and higher-order site correlations within RNA-virus
proteins [10-17] employing various approaches such as
information theory, non synonymous versus synonym-
ous mutations, Bayesian networks, etc. Using generalized
kernel ridge regression and maximum entropy models,
others [17,18] have described a general and interesting
concept, which is the fitness landscape. Unfortunately,
their goal was not to make the difference between com-
pensatory mutations (CM) and SL pairs. Moreover, they
were not interested in pointing to potential druggable
sites, which is one of our main aims here. Further works
were specifically developed on the viral RNA SL but they
simulate them rather than detecting them [19,20].
In a preliminary work taking the HIV protease as a
model, [7,21,22], we described positions involved in SDL
couples. The method used yielded results comparable to
those obtained by other teams working on the same sub-
ject [23-25]. However, the sole knowledge of the amino
acid (AA) positions is just part of the molecular picture
and knowing the exact nature of the AAs involved in
the SDL couples is just as important. Moreover, a SDL
couple is not expected to exist alone, but rather within
the context of a mutational network involving other
couples of SDL and CM. Finally, to uncover functional
covariation we must exclude background linkage dis-
equilibrium (BLD). In sum, from a sequence alignment
and a three-dimensional structure, we developed a strat-
egy involving statistical tests, phylogeny, 3D structure
and binding sites for constructing an in silico tool that
predicts potential therapeutic targets. This tool has
been tested on two HIV proteins, the protease (PR) and
the reverse transcriptase (RT) and allowed us to describe
five targets consisting of SL and invariant positions
that should greatly minimize the emergence of drug
resistance.
Results and discussion
Steps to predict drug targets in silico
To define protein regions as potential druggable targets
avoiding therapeutic escape, we have focused on SDL cou-
ples (Figure four in [6]) and invariant positions located in
their vicinities. To do so, seven steps are necessary. We
need first to identify pairs of interdependent sites. They
were defined by examining the variant positions (those
having accumulated more than 0.3% of mutations). Specif-
ically, these variant positions were tested in pairs usingstatistical tests, described in the Material and Methods
(MM) section, commonly used to define dependencies be-
tween positions. Couples responding positively to 3 of the
4 tests were taken as interdependent pairs. A couple of
residues may co/anti-vary for two main reasons: they can
be either an interdependent couple (CM or SDL) or be de-
rived from BLD. Only SDLs qualify for druggable targets
not allowing therapeutic escape. SDL couples were defined
as those having a number of observed pairs of mutated
residues smaller than the number of expected pairs. Thus,
we have defined a dissimilarity coefficient ξ, which is nega-
tive for SDL couples, and positive for CM couples (see
Material and Methods). We filtered the results of this
exploration to keep only the pairs located on the protein
surface as it is the most accessible location for known
therapeutic targets (accessibility threshold greater than
25%, using the ASA software [26] and implemented by
Allan et al. [27] based on the 3D PR structure PDB
ID:1HSG [28] and 3D RT structure PDB ID:1DLO [29]).
Next, we had to prove that SDL couples did not derive
from a common ancestor (i.e. exclude BLD). Position
couples underwent a further test: for all codons under-
lying these two positions, we computed the number of
synonymous (S) and non synonymous (A) mutations. If
the number of non-synonymous mutation pairs (A-A)
was twice as much the number of synonymous mutation
pairs (S-S) we considered that this pair of codons under-
goes a positive selective pressure. Such pairs were there-
fore assumed not to derive from a common ancestor, in
other words, not derived from BDL (Figure 1E for PR and
2 in brown for RT). Keeping in mind the idea of suggest-
ing druggable targets, we retained only SDL couples that
were close in space (at less than 10 Å on the 3D struc-
tures). Finally, “invariant” positions (<0.3% of mutations at
the relevant position relative to the ancestral sequence),
although infrequent, can also be taken into account in
the design of inescapable drug targets. Thus, all invari-
ant positions being at less than 10 Å from SDL positions
were also kept. The last step was to determine the drug-
ability of a group of residues. As a first approach, we
used the Q-SiteFinder software to list most important
binding sites of a protein from its 3D structure.
Predicted drug targets
From sequence alignments (PR-NT/protease-non treated
group: 24656 sequences, PR-T/protease-treated group:
10585 sequences, RT-NT: 23052 sequences and RT-T:
9784 sequences), all pairs of variant positions close in
space, on the surface were tested for interdependence.
To this end, we used four tests: the Fisher’s exact test
(Figure 1A for PR and 2 in the black area for RT), χ2
(Figure 1B for PR and 2 in the blue area for RT) D’
(Figure 1C for PR and 2 in the red area for RT), r2
(Figure 1D for PR and 2 in the green area for RT). When a
A B   C D E  
NT
PR
T
PR
Figure 1 Accessible covariation studies. Variant and accessible positions were tested by pair for covariation, if both positions are separated by
less than 10 Å. 4 different statistic tests were performed for both sets (sequence from treated T, and non-treated NT patients) and both proteins
(PR: protease, RT: reverse transcriptase): A: Fisher exact test, p-values <0.05 are shown. B: χ2ij p-values <0.05 are shown. C: D’, first described by Lewontin
[39] and used to detect gametic disequilibrium. This result is given if Θ is >1.5 or <0.5 [14]. The D’ coefficient has a value between −1 and 1. D: the
correlated coefficient r2. The result is given if Θ is >1.5 or <0.5 [14]. The r2-correlated coefficient has a value between 0 and 1. E: D’ coefficient was
calculated for non-synonymous pair of positions (A-A) as well as synonymous pair of positions (S-S). Their ratio, D’AA/SS identifies the background
linkage disequilibrium or in other words the fact that the sequences share a common ancestor. The result is given positive if D’AA/SS > 2.
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statistical tests, it becomes tagged as interdependent.
Figure 1E for PR and Figure 2 in the brown area for RT,
represent the BLD, the weaker it is, the bigger is the
chance for a pair of interdependent residues to comeFigure 2 Venn representation of the interdependent pairs in the RT p
the protein were examined using five statistical tests. Black numbers stand
from treated set of patients. χ2, D’, r2 and Fisher’s are statistical tests explain
MM. The shaded area corresponds to the pairs of interdependent residues,from a common ancestor. The pairs successful for 3 statis-
tical tests and not derived from a common ancestor are
represented on a heatmap for PR (Figure 1) and a Venn
Diagram for RT (Figure 2). We compared our results with
those of Rhee et al. [30]. Of the 49 interdependent pairsrotein. All variant pairs of residues close in space and at the surface of
for the results from non-treated set. Red numbers represent the results
ed in MM. BLD is a background linkage disequilibrium described in
having 3 valid statistical tests out of 4 and a BLD score > 2.
Petitjean et al. Biology Direct  (2015) 10:17 Page 4 of 13they describe for patients under anti-RT treatments, only
5 are close in space and on the surface of a RT. These five
couples are positive for our interdependence tests but two
of them where rejected by our BLD test. Indeed, this test
was not performed by Rhee et al. Concerning the PR, out
of 49 interdependent couples described by Rhee et al. [30]
only one is close in space and at the PR surface. We
found this positive one with our algorithm. Our previ-
ous results [7] and those of three other groups [23-25],
were also confirmed by this new strategy, excepted
those coming from BLD. Finally, to distinguish between
SDL and CM, we determine the dissimilarity coefficient
ξ for each pair of residues of each couple (Additional file 1:
Table S1 represents this result for PR and Additional file 2:
Table S2 for RT). All intermediate results, from the val-
idity of statistical tests to the SDL determination are
displayed in Table 1. These results show that half of the
interdependent couples come from a common ances-
tor. For the other half, only 50% involved SDL couples.
To identify groups of positions that will become our
future targets, the invariant positions located within
10 Å of a SDL couple were determined. The number of
SDL is 10 times higher in the RT-T groups than in the
other three groups. This result comes from the fact that
the RT is 5 times longer than the PR, and because the
sequences of the treated groups contain more muta-
tions. Next, SDL couples and the invariant positions in
their vicinity were gathered to form a graph. The sub-
graph positions of these graphs (in Table 2) represent
the potential future targets. PR-NT and PR-T graphs
(Figure 3 and 4) contain two subgraphs, the RT-NT
(Figure 5) graph has three and RT-T (Figure 6) graph,
seven. Note that, subgraphs containing only two positions
were excluded because they cannot form a realistic
binding site.
Are these targets really druggable?
The groups of positions composing these subgraphs are
predicted to be good targets to avoid resistance. How-
ever, to be of therapeutic interest, these targets should
also be a good binding sites, i.e. pocket-shaped and com-
posed of atoms that a small molecule can bind. As a firstTable 1 SDL determination process
PR RT
NT T NT T
Number of interdependent couples 19 23 130 296
Number of interdependent couples excluding BLD 7 8 46 145
Number of SDL couples excluding BLD 4 5 7 63
BLD: Background Linkage disequilibrium.
SDL: Synthetic deleterious and lethal.
PR: Protease.
RT: reverse trancriptase.
NT: non treated.
T: treated.approximation, we tested this possibility by using the
Q-siteFinder program [31]. From a three-dimensional PR
structure chosen from the Protein data bank, Q-siteFinder
determined 10 protein regions, which could form a binding
pocket. We then kept the positions in the intersection
between our subgraph results and Q-SiteFinder binding
pockets. Table 2 lists the AA groups that fulfill the 7 condi-
tions described at the beginning of this section. These
groups therefore are candidate therapeutic targets forming
predicted good binding sites with low potential to generate
drug-resistance. We have highlighted two of these groups
on the PR structure (Figure 7A). The first one, containing
positions 12, 14, 19 (T1 in blue on Figure 7A, numbered in
Table 2), has a site volume of 103 Å3 and is common for
patients treated and untreated patients. The second one
containing positions 40, 42, 61 (T2 in red on Figure 7A,
numbered in Table 2) with a site volume of 82 Å3, can
only be used for untreated patients. Interestingly, stud-
ies of Bonhoeffer’s [17] group on fitness landscape, de-
scribed the same regions and defined them as
characterized by strong epistasis. These regions have
previously been described as being important for pro-
tein function [32]. The two best-scoring targets defined
by the Q-SiteFinder software, correspond to the active
site of the PR. The majority of drugs (not to say all)
against this protein bind to its active site but, unfortu-
nately, resistance against all these molecules have ap-
peared. Besides, we did not find SDL in those areas. We
have highlighted three of these groups on the RT struc-
ture (Figure 7B). The first one, containing the positions
13, 14, 15, 86, 17 (T3 in blue on Figure 7B, numbered in
Table 2), has a site volume of 243 Å3 and is common for
treated and untreated patients. Of note, the position 86
disappears from the treated group. This target is local-
ized in the RT fingers. The second one, localized in the
thumb and containing positions 259, 262, 263, 266 (T4
in red on Figure 7B, numbered in Table 2) with a site
volume of 375 Å3, only appears in the untreated set.
The last one, involving positions 63, 64, 65, 66, 67, 70,
72 (T5 in yellow on Figure 7B, numbered in Table 2)
with a site volume of 252 Å3 and localized in the RT
palm, is relevant for the treated set only. Interestingly,
the second and third targets are involved in the DNA
binding process.
Thus far, these results do not tell us anything about
the nature of the AAs involved in these couples. Indeed,
a given position can be involved in both CM and SDL
relationships (concerning two different AA) with other
positions and these relationships are interdependent. For
this reason, we also compiled a list of the specific AAs
involved in all the SDL and the CM couples, because they
influence the general mutational landscape of the protein.
All AA couples located at these positions and their dis-
similarity coefficients ξ are listed in the Additional file 1:
Table 2 SDL + INV groups
SDL + Inv* Binding site Site Volume
Protease NT 35, 61, 37, 72, 40, 34, 42, 81 40 + 42 + 61 103
12, 14, 19, 21 12 + 14 + 19 82
T 35, 37, 81, 45, 40, 46, 42, 52, 44
12, 14, 19, 21 12 + 14 + 19
63, 72
Reverse Transcriptase NT 35, 39, 40, 48,43, 44, 210, 215, 4, 29, 42, 1, 45, 113, 212
83, 86, 13, 89, 14, 93, 157, 15, 16, 17 13 + 14 + 15 + 86 + 17 243
194, 200, 192, 203, 199, 222
243, 226, 245, 240, 259, 262, 263, 268, 266, 265 259 + 262 + 263 + 266 375
6, 9
T 394, 395,33, 355, 415, 399, 332, 357, 326, 418, 421, 424, 426
199, 197, 203, 200, 204, 207, 210, 211, 43, 39, 212, 110, 157, 48,
44, 4, 113, 215, 184, 42, 40, 1, 151, 218, 219, 185, 45, 152, 222
68, 67, 69, 70, 72, 290, 291, 64, 65, 63, 292, 250, 66, 294, 296, 297 63 + 64 + 65 + 66 + 67 + 70 + 72 252
82, 83, 16, 13, 14, 15, 17 13 + 14 + 15 + 17 243
321, 323, 324, 238, 344, 346, 345, 347, 348, 351
32, 28, 23, 137, 24, 29, 25
166, 169, 173, 170, 174, 177, 192
122, 9, 126, 51, 52, 55
226, 228
243, 245
101, 237
*at the protein surface and close in space.
Petitjean et al. Biology Direct  (2015) 10:17 Page 5 of 13Table S1 for PR and Additional file 2: Table S2 for RT. In
these tables, it appears very clearly that SDL and CM cou-
ples are not necessarily the same between treated and un-
treated patient sets. That is, couples can covary in one set
and not in the other one (e. g. 45–46, 61–72, 63–72 forFigure 3 Graph representation of SDL and invariant interactions in PR
of 4 and 8 positions. A link between two position means that these two po
a red link binds two SDL position. A green link binds a SDL position to an
numbers correspond to the HIV PR positions.PR). Regarding the RT, the number of SL couples for
the untreated set is much smaller than the number of
couples in the treated set (Table 1), which means that
many couples are not common to both groups. Obvi-
ously, the potential druggable targets themselves are not-NT. 2 sub-graphs derived from our computational analysis, composed
sitions are at the surface of the protein and close in space. Moreover,
invariant position. Finally, a blue link binds two invariants positions. The
Figure 4 Graph representation of SDL and invariant interactions in PR-T. 2 sub-graphs derived from our computational analysis, composed
of 4 and 9 positions. A link between two position means that these two positions are at the surface of the protein and close in space. Moreover,
a red link binds two SDL position. A green link binds a SDL position to an invariant position. Finally, a blue link binds two invariants positions. The
numbers correspond to the HIV PR positions.
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keeping this in mind, a potential drug can be able to block
RT or PR in naïve patients, in treated patients or both.
How to interpret the fact that the targets we describe
lie outside the active sites? The residues constituting
the protein active site are generally responsible for the
chemical reaction allowing the enzymatic activity of the
protein. However, the active site is not the only essential
part of a protein as this function is carried by its three-
dimensional structure. Protease studies [33] show that
its very flexible structure allows the flaps to open in
order to accommodate its substrate. It is obvious thatFigure 5 Graph representation of SDL and invariant interactions in RT
of 6, 10, 11 and 15 positions. A link between two position means that thes
Moreover, a red link binds two SDL position. A green link binds a SDL posi
positions. The numbers correspond to the HIV RT positions.opening the flaps is an essential function for the en-
zymatic activity. It is therefore quite possible to block
an essential function without docking a drug directly in its
active site. The best examples are the existence of the
non-nucleosidic reverse transcriptase inhibitors.
In the future
We would like to develop a software able to generate a
table of interdependent residues and to sort out the best
AA groups to uncover inescapable drug targets. Such a
strategy can be applied to any protein, especially those
from RNA viruses such as flu [34], coronavirus [35],-NT. 4 sub-graphs derived from our computational analysis, composed
e two positions are at the surface of the protein and close in space.
tion to an invariant position. Finally, a blue link binds two invariants
Figure 6 Graph representation of SDL and invariant interactions in RT-T. 8 sub-graphs derived from our computational analysis, composed
of 6, 7, 7, 7, 10, 13, 16 and 29 positions. A link between two position means that these two positions are at the surface of the protein and close
in space. Moreover, a red link binds two SDL position. A green link binds a SDL position to an invariant position. Finally, a blue link binds two
invariants positions. The numbers correspond to the HIV RT positions.
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quences are available in the databases. These best inter-
dependent AA groups could then be tested to assess
whether their 3D arrangements form a druggable pocket
at the protein surface. Q-SiteFinder allows a first ap-
proximation for pocket detection that will be enriched
with studies that consider the flexible nature of the pro-
teins, to discover the most suitable pockets. This tech-
nique allows the description of potential targets, which
must be biologically validated, to prove they carry essen-
tial functions.
Viral fitness is one of the major aspects of the thera-
peutic escape along with variation and interdependence.
Drugs increase the selection pressure and then alter the
general mutational landscape of the target viral protein.
Indeed, several positions are mutated in the treated set,
which generate/maintain viral drug resistance. These
new mutations can have a drastic impact on the fitness
of the virus, and several other positions could also mu-
tate to maintain/increase the fitness of these newly mu-
tated viruses. It could be interesting to create a sequence
database, where each sequence would be associated with
a viral fitness measure [17], such as its average copy
number in the blood. With this information in hand and
based on the quasi-species theory principles [37], it
would be easy to test if the existence of SDL groups in a
sequence can be correlated with a low fitness (i.e. a low
copy number). Thus, we could show that to escape a
drug, a virus will have to make mutations within SDL
groups and to pay the price for, by decreasing its repli-
cation potential.
Conclusion
The choice of SDL and invariant positions as unique
components of effective druggable targets has the ultim-
ate aim of reducing or even eliminating drug-resistance.Our results describe two new potential targets on PR
and 3 on RT. We offer an unusual strategy, since these
targets are not necessarily the same for the treated and
untreated patients. The drug-induced selection pressures
reveal new mutations that most often, reduce the fitness
of the mutated organism. Variants that possess mutations
enabling them to acquire better fitness, will now be se-
lected. These two successive waves of mutations change
the general equilibrium between CM and SDL in the two
patient sets, leading to different drug development strat-
egies. In the near future, it can be important to administer
different molecules to naive (never treated) patients and
to treated patients.
Sometimes a single mutation allows viruses to escape
treatment. If this mutation appears on a SL position, no
function will be lost. That is why in the description of
our target we include the invariant positions, which mu-
tated, prevent protein function. However, if this first mu-
tation appears alone, we reach the limit of our strategy
and resistance can develop. Our target will be unusable as
it will be the equivalent of the targets described in the
past. However, drug docking on targets consisting of
invariant residues and SL pairs, is the best way to block
viral resistance.
Wet biology can only describe an existing situation
where residues appear to mutate concomitantly to induce
resistance against a PI. Conversely wet biology cannot as-
sess a situation where two residues are required to mutate
together to induce resistance (but entailing the loss of an
essential function). Indeed, this situation never appears.
Here, we have focused on the kind of couples constituted
by SDL and not by CM to describe new potential protein
pockets that could be bound by potential drugs. If we were
able to do so, HIV virus could not escape treatment
without loosing an essential function. Additional file 1:
Table S1 summarizes these interdependence relationships
BA
Figure 7 3D view of the potential target sites. A: The different
target sites are shown on a 3D representation of the HIV-1 homodimer
(1HSG) PR. The red target is lining a pocket necessary for the opening
of the flaps. The blue one in located in the fulcrum of the protein.
B: The different target sites are shown on a 3D representation of
the HIV-1 homodimer (DLO1) RT. The red and the yellow targets are
lining a pocket necessary for docking DNA. The color residues are
those constituting of SDL groups and forming a binding site according
to the results given by the Q-siteFinder software. The 3D molecules of
the A and B panel were built by pymol software [43].
Petitjean et al. Biology Direct  (2015) 10:17 Page 8 of 13(i.e. a look-up table describing the exact AAs forming CM
or SDL).
The method described in this manuscript is applied to
HIV but can be used on any sequence dataset. In fact
the only limitation is the total number of mutations per
position. Indeed, in order to study the ability of two po-
sitions to mutate simultaneously or not, it is necessary
to prove that each of these positions is variable. RNA
viruses mutate approximately 100 times faster than most
other organisms. This ability allows these species to be
prime candidates for our method. However, since the
number of sequenced genomes being constantly increased,
it is almost certain that in the near future, this method willalso be used to find new drugs against bacteria for which
antibiotic resistance are becoming a major problem of
public health.
Most drugs have been developed based on their ability
to bind active sites. They can therefore bind the active
sites of similar proteins and thus generate possible side
effects. Our technique allows to target regions outside of
the active sites, which might help define drugs with
fewer side effects.
As already said, it will be necessary to experimentally
validate these bioinformatic predictions. For this, it is
important to prove that the targets are essential for
protein function. This question could be addressed by
studying how the mutation of the residues composing
the targets will affect viral activity. Small molecules
binding the target at the selected positions can be found
using virtual high throughput screening of large chem-
ical libraries. Potential leads emerging from these hits
may be refined by structure-activity studies. Finally, in-
hibition of viral activity in the presence of these mole-
cules should validate the quality of the inhibitor.Methods
Construction of sequence data sets
24656 PR sequences and 23052 RT sequences of HIV-1
subtype B, from non-treated patients were downloaded
the 7th of May 2013, from the Stanford University HIV
drug resistance database [38] (http://hivdb.stanford.edu/).
10585 sequences, from patients treated with 1 to 9 PI were
downloaded as well and 9784 RT sequences from pa-
tient with 1–7 NRTI and/or 1–4 NNRTI. The sequences
of these two protein sets are full length i.e. containing
the 99 positions of the PR, 560 positions for the RT.Identification of the accessible variant positions
In order to define the accessibility of the AAs to an exter-
nal ligand (i.e. a potential drug), we computed the surface
accessible to the solvent, using the ASA software [26]
available at RPBS [27], based on the 3D PR structure PDB
ID:1HSG [28] and 3D RT structure PDB ID:1DLO [29].
All AAs having an accessibility threshold greater than 25%
are considered “accessible”.Recoding alignment
Previous protein alignments were recoded to focus the
mutated AA status relative to a reference sequence. Each
AA was compared to the AA from the ancestral sequence
in the same position. It is recoded in 1 if it is equivalent to
the ancestral sequence, 0 otherwise and N if it is not de-
fined. Only positions lying on the surface of the protein
and variants (ie with more than 0.3% of mutated positions)
have been taken into account.
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A couple were defined as interdependent if 3 of the fol-
lowing 4 statistical tests.
1. The Fisher exact test of covariance coded in R was
used to examine each variant position pairs of PR
and RT. To overcome the bias caused by the large
number of tests performed, the p-values were
re-adjusted using a FDR method in R. After this
adjustment, only p-values > 0.05 were retained. The
pairs corresponding to these p-values are black on
the heatmap of Figure 1 and numbered in the black
area on figure 2 for RT.
2. The D’ test measures the linkage disequilibrium
[39,13,40] which is the non-random association
calculation of two alleles at two loci. This D’ test
has been computed for all pairs of positions
variants and accessible (using as input the recoding
alignments according to Wang data’s [13]). The
pairs corresponding to these p-values are the “non
red” on the heatmap of Figure 1 and numbered in
the red area on Figure 2 for RT.
3. r2 [41] is an index derived from the correlation
index D Lewontin [39,13,40]. Using recoding
alignments, this test r2 has been computed in
Perl according to (13, 32, 33) for all pairs of
positions variants and accessible. The pairs
corresponding to these p-values are black on
the heatmap of Figure 1 and numbered in the
green area on Figure 2 for RT.
4. This last test is a χ2ij that takes into account the true
nature of AA and not just the fact that it is mutated
or not. It is thus calculated from the protein
alignment (not recoded) of the method according
Noirvirt [42]. In these conditions, only couples
expected more than 5 times were kept. Given a
p-value of 0.05 in the sense of [42], we calculated
that 6% of the couples of positions that are detected
using the random shuffling method are due to
multiplicity (i. e. FDR) for the three sets. The pairs
corresponding to these p-values are black on the
heatmap of Figure 1 and numbered in the blue area
on Figure 2 for RT.
Determination of background linkage disequilibrium (BLD)
Using DNA sequences, couples of non synonymous (A-A)
and couples of synonymous mutations (S-S) were deter-
mined. A D’ coefficient were then computed from these
data as explained in [13,14]. A couple were determined
as free from BLD if D’(A-A)/D’(S-S) > 2. To simplify D’(A-
A)/D’(S-S) is written D’AA/SS. The pairs corresponding to
these p-values are “non brown” on the heatmap of Figure 1
for PR and numbered in the brown area on Figure 2
for RT.Partition the interdependent pairs in CM and SDL
When a couple was determined as interdependent, one
can compute a signed dissimilarity coefficient ξ which is
negative when the number of expected AA couple were
superior of the number of observed couples (SDL pairs),
otherwise it is a compensatory pairs (CM).
Furthermore this coefficient is here conventionally
signed as follows:
If NobsA,i,B,j ≥NexA,i,B,j then ξA,i,B,j = + χ
2
A,i,B,j
Otherwise it is negative
If NobsA,i,B,j <NexA,i,B,j then ξA,i,B,j = − χ
2
A,i,B,j
Where “A” is a specific AA at position “i”, “B” is a spe-
cific AA at position “j” and χ2A,i,B,j is computed as in [42].
Reviewers’ comments
Reviewer’s report 1
Reviewer 1: N. Greenspan, Case Western Reserve Uni-
versity, United States of America
Reviewer’s comment
Petitjean et al. describe an interesting strategy for minimiz-
ing mutational escape of HIV from therapeutic agents
targeting either protease (PR) or reverse transcriptase (RT).
Based on amino acid sequence alignments from either
treated or non-treated individuals, they identified amino
acids that appear to be accessible and lethal or deleterious
when simultaneously mutated (synthetic lethal, SL, or syn-
thetic deleterious, SD, residues). The authors also identify
apparently invariant PR and RT amino acids that are there-
fore assumed to be critical for molecular function.
The central hypothesis being pursued is that drugs
able to bind to such SL/SD pairs that are in sufficient
proximity to one another, plus one or more amino acids
identified as invariant, on the molecular surface would
serve as relatively non-mutable target sites for inhibitory
drugs. Success in their objective would be of obvious
value in the efforts to minimize the spread of HIV and
the management of infection in individuals already car-
rying HIV. In the present manuscript, the authors also
demonstrate that exposure to treatment modifies the PR
and RT mutational landscapes.
1. Given that the contents of the present manu-
script have employed methods already described in a
previous article (Brouillet et al., Biology Direct 2010,
5:40 doi:10.1186/1745-6150-5-40), although with an ex-
panded range of application, I would have appreciated
experimental data testing the critical assumptions of the
analysis. More specific concerns are delineated below.
Authors’ response
The reviewers’ comments of our first article enabled us to
significantly change the method used. Indeed, our previ-
ous method does not solve three important points:
Petitjean et al. Biology Direct  (2015) 10:17 Page 10 of 13– Discrimination of pairs of residues functionally
interdependent of those that are due to a common
ancestor. To answer to reviewer 3 of the previous
article, we used a ‘D’ Lewontin derivative test. This
new test is used to compare the rates of
synonymous and non synonymous mutations for
pairs of positions.
– Statistical studies were based on a single test. Three
other tests were implemented (D’, r2, fisher).
– The nature of the amino acids was not taken into
account and only the Boolean result “mutated/
non-mutated” was calculated. New statistical tests
now allow to define the exact nature of AAs forming
interdependent couples.
Applications All findings concerning RT are new results
since the first paper concerned only the PR that has
served as a control in this new study.
Two tables (RT, PR) describe the major pairs of muta-
tions and the nature of the associated amino acids for the
4 sequence sets (Additional file 1: Tables S1 and Additional
file 2: Table S2). These tables are essential for drug de-
signers, chemists and chemoinformaticians.
Regarding the biological validation of these results: this
is beyond the scope of the present paper but we are
currently setting up a partnership with a HIV virology
laboratory that will define the adequate experimental
protocol and apply it.
Reviewer’s comment
2. I am not confident that 100% of “invariant” residues
are in fact critical for function. For example, a putatively
invariant tryptophan residue at the start of the second
framework region within all immunoglobulin heavy and
light chain variable domains sequenced prior to the study
by J. Sharon [J Immunol. 1988 Apr 15;140(8):2666–9] was
found not to be critical for function. For an antibody of
known antigen specificity, Sharon mutated the Trp to Ala
by site-directed mutagenesis without apparent effect on
antibody reactivity for antigen.
Authors’ response
We agree with this comment. However, although we
cannot say that every invariant site is essential for pro-
tein function, the contrary seems to be a special and not
very widespread situation. All invariant amino acids or
group of invariance (SL) cannot all be in this case. So,
most of “invariant + SL” group are supposed underlie es-
sential functions.
Reviewer’s comment
3. Another assumption critical to the authors’ thesis is that
drugs able to bind the sites identified as including SL/SD
and invariant residues will effectively inhibit function foreither PR or RT. I would not be surprised if some such
drugs would exhibit disappointing levels of inhibitory ac-
tivity, so that mutational escape would not be essential for
the virus to continue to replicate.Authors’ response
It could indeed be the case, as it has been in the past for
many other inhibitors whose development does not, how-
ever, relied on the strategy described in this paper. We can
not predict in advance the strength of an inhibitor. More-
over, our method describes the target and not the inhibi-
tors themselves.Reviewer’s comment
4. Experimental testing will also help to address the con-
cern raised by reviewers of the 2010 article by Brouillet
et al. that evolutionary history may confound the identi-
fication of SL/SD amino acid pairs.Authors’ response
It is thanks to the previous reviewer proposals that we
set up a new test to select pairs of residues that interact
for functional reasons and not for sharing a common an-
cestor (see answer to question 1). However, experimental
testing is beyond the scope of this paper.Reviewer’s comment
5. The authors appear to assume that synonymous mu-
tations are selectively neutral. There are precedents for
synonymous mutations that affect fitness through effects
on RNA structure that influence the rate of translation
or through other mechanisms [e.g., see Science. 2007 Jan
26;315(5811):525–8; reviewed in Chamary et al. Nat Rev
Genet. 2006 Feb;7(2):98–108].Authors’ response
We agree with the comment of the referee. Synonymous
mutations may affect RNA secondary structure, and
even (indirectly) protein translation and conformation.
How does this affect our results? Our method involves
counting the non-synonymous and synonymous muta-
tions per codon pairs. If the ratio is close to 1, we con-
clude that these codons are not subject to selection
pressure and therefore the interdependence of residues
comes from a shared common ancestor. False negatives
could be obtained (ratio = 1). This requires the number of
non-synonymous mutation pairs (numerator) selected by
drug pressure to be similar to the pairs of synonymous
mutations. Although this is possible in principle, we be-
lieve this phenomenon is less frequent than a direct im-
pact of a mutation on the protein sequence. However, this
deserves exploration in a further study.
Petitjean et al. Biology Direct  (2015) 10:17 Page 11 of 13Reviewer’s report 2
Reviewer 2: Csaba Pal, Biological Research Center,
Hungary.Reviewer’s comment
The main objective of the paper is to identify intragenic
pairs of residues that show synthetic lethal interactions
in HIV proteins. The authors use this information to un-
cover drug target sites that could potentially mitigate the
evolution of resistance. The manuscript is well written
and the presentation of ideas goes straight to the point.
The strategy followed by the authors is, to my knowledge,
innovative and a valid approach to try to overcome drug
resistance during HIV therapy.
In fact, such approach, due to its target specificity and
efficiency, would also be beneficial to the development
of therapeutic approaches with less toxic side effects to
the therapy of new-borns, infants and young children,
which, together with multi-drug resistance, is an import-
ant problem to be solved in HIV therapy. The idea of
creating a software tool for the identification of inescap-
able drug targets is very important, and could help me-
dicinal chemists to focus their research on compounds
that bind to the predicted target sites.
The authors should discuss the benefits and future
perspectives of the work more deeply in the paper. For
example, the possibility to apply such methodology to
other target proteins should also briefly be discussed in
the manuscript. The authors should also discuss in vitro/
in vivo validation of the reported results, including pos-
sible limitations of such studies.Authors’ response
We thank the referee for these suggestions and will ac-
cordingly change the manuscript:
– This method, which is based on SL approach and
not through the development of competitive
inhibitors, could enable the discovery of less toxic
molecules, which are necessary to treat more
vulnerable patients.
– We suggest that it would be possible to do similar
studies on other RNA virus proteins.
– We also explain the biological tests that will be
required to validate the method and the limitations
of such techniques.
These changes will be highlighted in yellow in the text.Reviewer’s report 3
Reviewer 3: István Simon, Institute of Enzymology,
Hungary.Reviewer’s comment
This paper is a follow-up of a few papers by Anne Vanet
and coworkers on synthetic lethals. I recommend its pub-
lication after some revisions. First, the authors should clar-
ify what the novel findings of this paper are.
Authors’ response
(See the reply to reviewer 1 comment 1).
Reviewer’s comment
Also the druggable nature of a target should be checked
by in silico docking, using large drug datasets and fast
docking programs.
Authors’ response
We thought to check the druggable nature of the target
with in-silico docking using large datasets. However, as far
as we know, all currently available docking programs need
to initialize crucial parameters before being launched.
Among them, there are the initial location and orientation
of each chemical in the cartesian coordinates system of
the target. The optimal selection of these parameters de-
pends both on the target and on the ligand. It means that
writing the script to launch the docking is a complex task,
which may not be immediately successfull. Moreover, even
when working on known target-ligand complexes, it is
known that, most of the time, the correct pose is not re-
trieved as the first one ranked by the docking software,
and this correct pose is more likely to be found among the
ten or the twenty best poses, if ever found. Their manual
analysis (e.g. with graphical tools) is difficult even for a
small number of chemicals, so the automatic analysis of
the results for large datasets is a complex task, too. Thus
we feel that the requested in silico checking cannot be
done at the occasion of a minor addition of the paper. In-
deed, it should be the focus of a full scientific project.
Reviewer’s comment
There are some minor issues. The reference of the se-
quence data and not only the URL should be given.
Authors’ response
We will provide the reference of the sequence dataset.
Tang MW, Liu TF, Shafer RW. (2012). The HIVdb
system for HIV-1 genotypic resistance interpretation.
Intervirology 2012;55(2):98–101. Epub 2012 Jan 24.
Reviewer’s comment
Also the reference for Pymol should be included.
Authors’ response
The version used in this work is MacPyMOL0.99 To our
knowledge, this software has never been published.
Petitjean et al. Biology Direct  (2015) 10:17 Page 12 of 13Reviewer’s comment
It is reasonable that some drug, which fits to the PR-NT
and RT-NT cases can not be used for PR-T and RT-T
cases, but it is not clear why they are not usable the
other way around.
Authors’ response
We agree with the referee, the opposite case is more
complicated to understand. In fact, we must keep in
mind that the pairs of SL and CM are embedded within
a complex network of pairs that evolves when an indi-
vidual node of the network changes. Thus, in the treated
patient sequence sets, several mutations occur in response
to the selection pressure and the drugs developed for un-
treated patients may no longer work for most patients.
These new mutations could cause a modification of the
mutational landscape and reveal new pairs of SL, of course
only in the treated patient sets. New drugs based on these
SL should therefore be effective on treated patients and
not on untreated patients.
Re-reviewer’s report 3
Reviewer 3: István Simon
Reviewer’s comment
I understand that the authors are not willing to make
the docking calculations in the present paper, so the
paper can be published without it. However if they are
willing to do it in a later paper, I suggest to consult the
paper: Volkamer A. et al. Bioinformatics 28 (15) 2074–
2075; 2012 to learn how to do it without prior know-
ledge of the binding sites.
Also, I would like to call their attention to the notice
of the current distributor of PyMOL:
Like many software programs PyMOL was not pub-
lished. It does not have a scientific algorithm one can
publish. Still it is necessary to cite it. You can find in-
structions on how to do that here: http://www.pymol.
org/citing
I suggest to consider it even for this paper.
Additional files
Additional file 1: Table S1. SDL and CM pairs in PR for untreated and
treated sets. Observed/expected pairs and dissimilarity coefficient for
each SDL and CM important pairs for PR.
Additional file 2: Table S2. SDL and CM pairs in RT for untreated and
treated sets. Observed/expected pairs and dissimilarity coefficient for
each SDL and CM important pairs for RT.
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